Passage Bio Inc is a genetic medicines company... Show more
The 10-day moving average for PASG crossed bullishly above the 50-day moving average on August 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on September 10, 2025. You may want to consider a long position or call options on PASG as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
PASG moved above its 50-day moving average on August 14, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PASG advanced for three days, in of 211 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 86 cases where PASG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 38 cases where PASG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PASG turned negative on September 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PASG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PASG broke above its upper Bollinger Band on August 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.587) is normal, around the industry mean (20.221). P/E Ratio (0.179) is within average values for comparable stocks, (53.359). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.167). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (333.789).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PASG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PASG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a genetic medicines company, which focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options
Industry Biotechnology
A.I.dvisor indicates that over the last year, PASG has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PASG jumps, then AXON could also see price increases.
Ticker / NAME | Correlation To PASG | 1D Price Change % | ||
---|---|---|---|---|
PASG | 100% | +0.86% | ||
AXON - PASG | 43% Loosely correlated | +2.13% | ||
CYTK - PASG | 38% Loosely correlated | +0.97% | ||
ARRY - PASG | 35% Loosely correlated | +3.41% | ||
VYGR - PASG | 32% Poorly correlated | +3.87% | ||
ANTX - PASG | 32% Poorly correlated | +6.03% | ||
More |